Pharsight

Aemcolo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741948 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(10 months from now)

US8529945 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(10 months from now)

US8263120 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(10 months from now)

US8486446 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(10 months from now)

Aemcolo is owned by Redhill.

Aemcolo contains Rifamycin Sodium.

Aemcolo has a total of 4 drug patents out of which 0 drug patents have expired.

Aemcolo was authorised for market use on 16 November, 2018.

Aemcolo is available in tablet, delayed release;oral dosage forms.

Aemcolo can be used as treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults.

Drug patent challenges can be filed against Aemcolo from 17 November, 2027.

The generics of Aemcolo are possible to be released after 16 November, 2028.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2023
Generating Antibiotic Incentives Now(GAIN) Nov 16, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using RIFAMYCIN SODIUM ingredient

NCE-1 date: 17 November, 2027

Market Authorisation Date: 16 November, 2018

Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage

AEMCOLO family patents

Family Patents